Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background: Real-world clinical data concerning regdanvimab, a monoclonal antibody treatment for patients with mild-to-moderate coronavirus disease 2019 (COVID-19), are urgently needed. Here, we describe our experience with regdanvimab. Materials and methods: This retrospective cohort study enrolled high-risk adults with mild-to-moderate COVID-19 who were admitted to a dedicated COVID-19 hospital in Korea from March to September 2021. We used multiple logistic regression and propensity score-matching to compare the outcomes of patients who did or did not receive regdanvimab. The primary outcome was in-hospital progression to severe or critical status, or death. Results: Of 586 patients eligible for regdanvimab, 256 patients who received regdanvimab and 251 untreated patients were included. The median age was 66 years and 47.5% were men. The most common underlying illnesses were hypertension (53.8%) and diabetes (36.9%). Patients were admitted to the hospital at a median of 2 days after symptom onset; regdanvimab was administered at a median of 3 days after symptom onset. Multivariate analysis indicated that regdanvimab significantly reduced the risk of disease progression during hospitalization [odds ratio (OR): 0.285; 95% confidence interval (CI): 0.144 - 0.564]. In a 1:1 propensity score-matched cohort (172 patients in either group), regdanvimab also decreased the risk of progression (OR: 0.162; 95% CI: 0.068 - 0.386). Conclusion: In high-risk patients with mild-to-moderate COVID-19, regdanvimab decreased the risk of progression to severe COVID-19.
Abstract
Background: Real-world clinical data concerning regdanvimab, a monoclonal antibody treatment for patients with mild-to-moderate coronavirus disease 2019 (COVID-19), are urgently needed. Here, we describe our experience with regdanvimab. Materials and methods: This retrospective cohort study enrolled high-risk adults with mild-to-moderate COVID-19 who were admitted to a dedicated COVID-19 hospital in Korea from March to September 2021. We used multiple logistic regression and propensity score-matching to compare the outcomes of patients who did or did not receive regdanvimab. The primary outcome was in-hospital progression to severe or critical status, or death. Results: Of 586 patients eligible for regdanvimab, 256 patients who received regdanvimab and 251 untreated patients were included. The median age was 66 years and 47.5% were men. The most common underlying illnesses were hypertension (53.8%) and diabetes (36.9%). Patients were admitted to the hospital at a median of 2 days after symptom onset; regdanvimab was administered at a median of 3 days after symptom onset. Multivariate analysis indicated that regdanvimab significantly reduced the risk of disease progression during hospitalization [odds ratio (OR): 0.285; 95% confidence interval (CI): 0.144 - 0.564]. In a 1:1 propensity score-matched cohort (172 patients in either group), regdanvimab also decreased the risk of progression (OR: 0.162; 95% CI: 0.068 - 0.386). Conclusion: In high-risk patients with mild-to-moderate COVID-19, regdanvimab decreased the risk of progression to severe COVID-19.
참고문헌 (25)
- "WHO coronavirus (COVID-19) dashboard" (2021)[URL]
- Cen Y, "Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study", Clin Microbiol Infect, 26, pp.1242~1247 (2020)
- Gandhi RT, "Mild or moderate Covid-19", N Engl J Med, 383, pp.1757~1766 (2020)
- Gupta A, "Early treatment for Covid-19 with SARSCoV-2 neutralizing antibody sotrovimab", N Engl J Med, 385, pp.1941~1950 (2021)
- Weinreich DM, "REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19", N Engl J Med, 384, pp.238~251 (2021)
- Dougan M, "Bamlanivimab plus etesevimab in mild or moderate Covid-19", N Engl J Med, 385, pp.1382~1392 (2021)
- Chen P, "SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19", N Engl J Med, 384, pp.229~237 (2021)
- Marovich M, "Monoclonal antibodies for prevention and treatment of COVID-19", JAMA, 324, pp.131~132 (2020)
- Kim C, "A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein", Nat Commun, 12, pp.288~ (2021)
- "Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59"[URL]
- "Press release: Celltrion’s regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean MFDS"[URL]
- "EMA issues advice on use of regdanvimab for treating COVID-19" (2021)[URL]
- "Coronavirus (COVID-19), Republic of Korea. Patient treatment & management" (2020)[URL]
- "COVID-19 treatment guidelines. Clinical spectrum of SARS-CoV-2infection" (2021)[URL]
- Anderson B, "Effect of monoclonal antibody treatment on clinical outcomes in ambulatory patients with coronavirus disease 2019", Open Forum Infect Dis, 8, pp.ofab315~ (2021)
- Stuart EA, "Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research", J Clin Epidemiol, 66(8Suppl), pp.S84~S90 (2013)
- Bruzzesi E, "Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection", New Microbiol, 44, pp.135~144 (2021)
- Syed YY, "Regdanvimab : First approval", Drugs, 81, pp.2133~2137 (2021)
- ACTIV-3, "TICO LY-CoV555 Study Group", A Neutralizing monoclonal antibody for hospitalized patients with Covid-19, 2021, pp.384, 905~914
- "IDSA guidelines on the treatment and management of patients with COVID-19" (2021)[URL]
- Planas D, "Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization", Nature, 596, pp.276~280 (2021)
- Ryu DK, "The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2", Biochem Biophys Res Commun, 578, pp.91~96 (2021)
- "Enhancing response to Omicron SARS-CoV-2 variant" (2022)[URL]
- VanBlargan LA, "An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies", Nat Med, pp.1~6 (2022)
- "FDA statement. Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the omicron variant" (2022)[URL]